Data Collection Form (v3.1)				**Randomization Time** _____				**AT2 start time** _____	
Study No. _____				**Gender:** M ☐ F ☐			**Wt:**	**BMI:** ____	**Age:** _____
	Pre-	**0h**	**1h**	**3h**	**6h**	**12h**	**24h**	**48h**	**72h**
Vitals									
MAP									
Temp									
HR									
SpO2:									
FIO2:									
Labs									
Art. PH:									
pCO2									
PaO2:									
serum Na									
serum K									
serum HCO3									
serum Cl									
BUN									
serum Cr									
glucose									
WBC									
Hgb									
Platelet									
T bilirubin									
Renin/DPP3	/	/	/	/	N/A		/	N/A	N/A
	24h post drug discontinuation: /								
Pressors									
Norepi									
Vasopressin									
AngII									
Epinephrine									
Phenyleph.									
Dobutamine									
Milrinone									
Meth. Blue									
NED									
Other									
P/F:									
24h UOP									
GCS:									
SOFA									
SOFA Resp									
SOFA Neuro									
SOFA CV									
SOFA Liver									
SOFA Coag									
SOFA Renal									
Total SOFA									

Baseline Characteristics/Comorbidities/PMHx:

ACEi exposure: Yes ☐ No ☐ ARB exposure: Yes ☐ No ☐ Diabetes: Yes ☐ No ☐
Known DM complications: Yes ☐ No ☐ (if yes, specify type): _____ CAD/MI: Yes ☐ No ☐
CHF: Yes ☐ No ☐ (if yes, specify EF): _____ PVD: Yes ☐ No ☐ stroke/TIA: Yes ☐ No ☐

dementia: Yes ☐ No ☐ hemiplegia: Yes ☐ No ☐ COPD: Yes ☐ No ☐ asthma: Yes ☐ No ☐
connective tissue dz: Yes ☐ No ☐ (if yes, specify type): _____ PUD: Yes ☐ No ☐
liver disease: Yes ☐ No ☐ cirrhosis: Yes ☐ No ☐ (if yes, specify MELD at randomization): _____
known cirrhosis complications: Yes ☐ No ☐ (if yes, specify type): _____
CKD: Yes ☐ No ☐ (if yes, specify baseline SCr): ___ ESKD: Yes ☐ No ☐ (if yes, specify HD ☐ PD ☐ Txp ☐)
Solid tumor: Yes ☐ No ☐ (if yes, specify if metastatic Yes ☐ No ☐) Leukemia: Yes ☐ No ☐
Lymphoma: Yes ☐ No ☐ AIDS: Yes ☐ No ☐
Other Txp/immunocompromise: Yes ☐ No ☐ (if yes, specify type): _____

Vasopressors:
Norepinephrine:
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Angiotensin II:
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Vasopressin:
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Other Adrenergic Vasopressors (doses in combined NED):
Epinephrine ☐ Phenylephrine ☐ Dopamine ☐
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Inotrope Use:
Dobutamine ☐ Milrinone ☐
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Start Date: _____ Start Time: _____ End Date: _____ Duration (from start): _____
Duration (from randomization): _____ Max Dose: _____ Mean Dose: _____
Methylene Blue use: yes ☐ No ☐

ICU Stay (days): _____ **Hospital Stay** (days): _____
ICU survival: Alive☐ Dead ☐ ☐**Hospital survival:** Alive☐ Death ☐

Mechanical Ventilation: Yes ☐ No ☐
Initiation date/time: _____ Stopping date/time: _____ Duration: (days)_____
Re-initiation date/time: _____ Stopping date/time: _____ Duration: (days)_____
Ventilator-Free Days (in first 28d post-randomization): _____

RRT: Yes ☐ No ☐
RRT type: CRRT ☐ IHD ☐ Both ☐
Initiation date/time: _____ Stopping date/time: _____ Duration (days): _____
Re-initiation date/time: _____ Stopping date/time: _____ Duration (days): _____
RRT-Free Days* (in first 28d post-randomization): _____

ARDS: Yes ☐ No ☐

AKI: Yes ☐ No ☐
Peak Serum Cr (pre-RRT): _____
AKI Stage: 1 ☐ 2 ☐ 3☐

***Adverse Events:** Yes ☐ No ☐
DVT ☐ PE ☐ arterial thrombosis ☐ (specify type): _____ atrial fibrillation ☐ tachycardia ☐
lactic acidosis ☐ limb/digit ischemia ☐ intestinal ischemia ☐ thrombocytopenia ☐ hyperglycemia ☐
confirmed infection ☐ (specify type): _____ other ☐ (specify): _____

Notes:
*Defined as period of sustained freedom of RRT starting after last RRT; periods between RRT treatments are considered "on RRT."
†Safety events are *new* hospital-acquired events which developed *after* randomization.